404 related articles for article (PubMed ID: 11601117)
1. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
[TBL] [Abstract][Full Text] [Related]
2. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Parving HH; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S;
N Engl J Med; 2001 Sep; 345(12):861-9. PubMed ID: 11565518
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Keane WF; Lyle PA;
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
[TBL] [Abstract][Full Text] [Related]
4. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
Egan B; Gleim G; Panish J
Curr Med Res Opin; 2004 Dec; 20(12):1909-17. PubMed ID: 15701209
[TBL] [Abstract][Full Text] [Related]
5. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
[TBL] [Abstract][Full Text] [Related]
6. Advances in the treatment of diabetic renal disease: focus on losartan.
Rayner B
Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
[TBL] [Abstract][Full Text] [Related]
7. Losartan in diabetic nephropathy.
Perico N; Ruggenenti P; Remuzzi G
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
[TBL] [Abstract][Full Text] [Related]
8. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
9. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Circulation; 2004 Aug; 110(8):921-7. PubMed ID: 15302780
[TBL] [Abstract][Full Text] [Related]
10. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
Winkelmayer WC; Zhang Z; Shahinfar S; Cooper ME; Avorn J; Brenner BM
Diabetes Care; 2006 Oct; 29(10):2210-7. PubMed ID: 17003295
[TBL] [Abstract][Full Text] [Related]
12. The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).
Brenner BM; Cooper ME; de Zeeuw D; Grunfeld JP; Keane WF; Kurokawa K; McGill JB; Mitch WE; Parving HH; Remuzzi G; Ribeiro AB; Schluchter MD; Snavely D; Zhang Z; Simpson R; Ramjit D; Shahinfar S;
J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):328-35. PubMed ID: 11967819
[TBL] [Abstract][Full Text] [Related]
13. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
Remuzzi G; Ruggenenti P; Perna A; Dimitrov BD; de Zeeuw D; Hille DA; Shahinfar S; Carides GW; Brenner BM;
J Am Soc Nephrol; 2004 Dec; 15(12):3117-25. PubMed ID: 15579515
[TBL] [Abstract][Full Text] [Related]
14. [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving HH; Lehnert H; Brøchner-Mortensen J; Gomis R; Andersen S; Arner P
Ugeskr Laeger; 2001 Oct; 163(40):5519-24. PubMed ID: 11601118
[TBL] [Abstract][Full Text] [Related]
15. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
[TBL] [Abstract][Full Text] [Related]
16. ACE-I and ARBs in early diabetic nephropathy.
Mauer M; Zinman B; Gardiner R; Drummond KN; Suissa S; Donnelly SM; Strand TD; Kramer MS; Klein R; Sinaiko AR
J Renin Angiotensin Aldosterone Syst; 2002 Dec; 3(4):262-9. PubMed ID: 12584670
[TBL] [Abstract][Full Text] [Related]
17. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
[TBL] [Abstract][Full Text] [Related]
18. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Eijkelkamp WB; Zhang Z; Remuzzi G; Parving HH; Cooper ME; Keane WF; Shahinfar S; Gleim GW; Weir MR; Brenner BM; de Zeeuw D
J Am Soc Nephrol; 2007 May; 18(5):1540-6. PubMed ID: 17409317
[TBL] [Abstract][Full Text] [Related]
19. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
Agha A; Bashir K; Anwar E
Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
[TBL] [Abstract][Full Text] [Related]
20. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.
Kurokawa K; Chan JC; Cooper ME; Keane WF; Shahinfar S; Zhang Z
Clin Exp Nephrol; 2006 Sep; 10(3):193-200. PubMed ID: 17009077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
